Revolutionizing Allergy Care: Sublingual Immunotherapy for House Dust Mite Allergy

House dust mite (HDM) allergies affect a significant portion of the global population. A considerable number of people in India suffer from allergic rhinitis (AR), and many individuals with AR are affected by HDM allergies. The management of allergic conditions, such as AR and allergic asthma (AA), has predominantly depended on drugs providing symptomatic relief and avoidance measures. These approaches do not include disease-modifying drugs and have limitations, including incomplete relief, slow onset of action, lack or drop-off in efficacy with continued use, and frequent exacerbations. With multiple species of HDM in India and high rates of sensitization among patients with nasobronchial allergy, symptomatic management is inadequate. Allergen immunotherapy (AIT), including sublingual immunotherapy (SLIT), represents the only disease-modifying treatment for allergic conditions. Unlike subcutaneous immunotherapy (SCIT), SLIT has the advantages of being non-invasive, allowing at-home administration, and having a lower potential for anaphylactic reactions. This review highlights the need for SLIT and explores the mechanism and clinical benefits of this novel immunotherapy.